P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab
Pentsova E, Malani R, Fleisher M, Lin X, Omuro A, Groves M, Lin N, Melisko M, Lassman A, Jeyapalan S, Boire A, DeAngelis L, Raizer J. P05.10 Prospective evaluation of cerebrospinal fluid circulating tumor cells (CSF CTC) in patients with HER2 positive cancers and leptomeningeal metastases receiving treatment with intrathecal trastuzumab. Neuro-Oncology 2018, 20: iii304-iii304. PMCID: PMC6144227, DOI: 10.1093/neuonc/noy139.336.Peer-Reviewed Original ResearchCSF CTCsLeptomeningeal metastasesCellSearch systemCTC enumerationCSF cytologyTreatment responsePhase I/II dose escalation trialDose-escalation trialPositive CSF cytologyCycles of treatmentHER2-positive cancersCycle 1Number of CTCsIntrathecal trastuzumabIT trastuzumabLM progressionEscalation trialIntrathecal therapyRadiographic responseVentricular reservoirRadiographic worseningProspective evaluationPositive cancersHER2 expressionCerebrospinal fluid